What’s Trending?

BioMarin finally won FDA approval for Palynziq to treat the rare inherited blood disorder phenylketonuria, but with a dreaded black box warning on the label—and an estimated average cost of $192,000—analysts are already wondering whether the product will be the blockbuster it's expecting. [...]
Fri, May 25, 2018
Source FiercePharma
Merck & Co. was expecting big things from Eisai's Lenvima in March, when it agreed to shell out up to $5.8 billion on half of the liver cancer drug's sales. But in the first expansion bid since that deal, Lenvima has hit a snag. [...]
Fri, May 25, 2018
Source FiercePharma
AstraZeneca's immunotherapy Imfinzi already has an FDA approval for inoperable lung cancer patients who've responded to chemo and radiation—and that's something none of its rivals will be able to say for a while. Friday, it hit another key benchmark to stretch out that lead. [...]
Fri, May 25, 2018
Source FiercePharma
Are you carrying out work on behalf of charities?Would you like to do more in this area?If the answer is yes, tell the industry by entering the new, Charity Challenge today. [...]
Fri, May 25, 2018
Source PharmaTimes
The PharmaTimes Marketer of the Year Awards will return to London in November, alongside Communications Team of the Year and the all-new Sales Awards. Get involved with the 25th anniversary celebrations as this unique competition continues to raise standards, drive innovation and put patient outcomes at the centre of healthcare [...]
Fri, May 25, 2018
Source PharmaTimes
If not, you should. Now!Dr Jim Golby PhD FCIPD, co-chair of the competition's executive steering group (ESG) says: "I strongly believe that the newly imagined 2018 Pharma Sales Awards will provide a superb methodology for identifying and recognising the very best sales professionals in our Industry today.” [...]
Fri, May 25, 2018
Source PharmaTimes
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin's lymphoma. [...]
Fri, May 25, 2018
Source PharmaTimes
Astellas will cut 600 positions in Japan in an R&D and sales reorg; a GSK infectious disease veteran launches wins $260M to launch a China-focused biotech; Sun Pharma wins an FDA green light for its knockoff version of Johnson & Johnson's prostate cancer drug Zytiga; and more. [...]
Thu, May 24, 2018
Source FiercePharma
Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxidant-enriched multivitamin may decrease respiratory illnesses in people with cystic fibrosis (CF). The study, which was recently published online in the American Journal of Respiratory and Critical Care [...]
Thu, May 24, 2018
Source WorldPharmaNews
AstraZeneca
AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology. Having achieved 16 regulatory approvals across major markets (US, EU, Japan and China), AstraZeneca will be [...]
Thu, May 24, 2018
Source WorldPharmaNews
Boehringer Ingelheim
Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto (tiotropium/olodaterol) Respimat enables greater physical activity in patients living with COPD. VESUTO and OTIVATO data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO data was recently published in the American Journal of [...]
Wed, May 23, 2018
Source WorldPharmaNews
Researchers at King's College London have found that patients prescribed any of the 12 most commonly used antidepressants were 21% more likely to experience an episode of gain weight than those not taking the drugs, (after adjusting for other factors which might affect this result). The full research is published [...]
Wed, May 23, 2018
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews